Can I Take Resveratrol With AOD-9604?

Why This Question Matters

People stacking AOD-9604 with resveratrol typically pursue two overlapping goals: fat loss and longevity. AOD-9604 (the C-terminal fragment 176-191 of human growth hormone) targets adipocyte beta-3 adrenergic signaling [1]. Resveratrol, a polyphenol found in grape skins, activates SIRT1 and AMPK pathways linked to metabolic health and caloric-restriction mimicry [2]. The appeal of combining them is obvious. The evidence base for doing so safely, however, is thin.

No published trial, case series, or pharmacovigilance report has examined co-administration. That does not mean the combination is dangerous. It means clinicians and patients must reason from each compound's pharmacology rather than from direct interaction data.

What the Absence of Data Tells Us

An absence of reported interactions is common for investigational peptides paired with nutraceuticals. The FDA's FAERS database contains no signal for AOD-9604 paired with any dietary supplement [3]. This gap reflects limited surveillance, not confirmed safety.

How AOD-9604 Is Metabolized

AOD-9604 is a 16-amino-acid peptide. Like most small peptides, it is degraded by extracellular and intracellular peptidases rather than by cytochrome P450 enzymes in the liver [1]. Its half-life after subcutaneous injection is estimated at 15 to 30 minutes based on pharmacokinetic modeling from the original Metabolic Pharmaceuticals studies [4].

Peptide Clearance vs. Small-Molecule Clearance

This distinction matters. Traditional drug-drug interactions occur when two compounds compete for or inhibit the same CYP isoform (pharmacokinetic interaction) or act on the same receptor pathway (pharmacodynamic interaction). Because AOD-9604 bypasses hepatic phase I metabolism entirely, CYP-based pharmacokinetic interactions with resveratrol are mechanistically implausible [4].

Renal and Proteolytic Pathways

Peptide fragments of AOD-9604 are filtered renally. Patients with eGFR <60 mL/min/1.73 m² should discuss peptide clearance with their prescriber regardless of supplement use, because reduced renal function could extend exposure duration for any peptide [5].

How Resveratrol Is Metabolized

Resveratrol undergoes rapid and extensive first-pass metabolism. Oral bioavailability is <1% for unchanged trans-resveratrol in most human studies [6]. The primary metabolic routes are sulfation (SULT1A1, SULT1E1) and glucuronidation (UGT1A1, UGT1A9), producing resveratrol-3-O-sulfate and resveratrol-3-O-glucuronide as the dominant circulating forms [6].

CYP3A4 Inhibition: Relevant or Not?

In vitro, resveratrol inhibits CYP3A4 with an IC₅₀ of approximately 5 to 10 µM [7]. At standard oral doses of 250 to 500 mg daily, peak plasma concentrations of free resveratrol rarely exceed 0.5 µM due to rapid conjugation [6]. The clinical significance of CYP3A4 inhibition at these concentrations is minimal for drugs metabolized by CYP3A4, and irrelevant for AOD-9604, which is not a CYP3A4 substrate at all.

A 2010 randomized crossover study in 12 healthy volunteers (single-dose 1,000 mg resveratrol) found no statistically significant change in midazolam clearance, a gold-standard CYP3A4 probe [8]. This reinforces the point: at realistic doses, resveratrol's CYP inhibition stays in the test tube.

CYP1A2 Considerations

Resveratrol also inhibits CYP1A2 in vitro [7]. Again, this is irrelevant to AOD-9604 but worth noting for patients taking caffeine, theophylline, or other CYP1A2 substrates alongside both compounds.

Pharmacodynamic Overlap: The AMPK Connection

The one area where a true interaction could exist is pharmacodynamic. Both AOD-9604 and resveratrol appear to modulate AMP-activated protein kinase (AMPK) signaling, though through different upstream triggers.

AOD-9604 and Lipolysis

AOD-9604 stimulates lipolysis in adipose tissue by activating beta-3 adrenergic receptors and downstream AMPK phosphorylation in preclinical models [1]. A 2001 study in obese Zucker rats showed a 50% increase in fat oxidation over 14 days of AOD-9604 administration compared to vehicle [4].

Resveratrol and AMPK

Resveratrol activates AMPK through SIRT1-dependent deacetylation of LKB1 and through direct AMP-mimetic effects at higher concentrations [2]. In the RECHARGE trial (N=66, adults with metabolic syndrome), resveratrol 500 mg twice daily for 90 days improved HOMA-IR by 19.8% relative to placebo (P=0.03) [9].

Additive, Antagonistic, or Neutral?

Dual AMPK activation could theoretically be additive for fat oxidation. It could also increase the risk of hypoglycemia in patients already on metformin or insulin, because AMPK activation suppresses hepatic gluconeogenesis [10]. No study has tested this triple combination.

For patients on glucose-lowering medications who want to add both AOD-9604 and resveratrol, a stepwise introduction (one agent at a time, two weeks apart, with fasting glucose monitoring) provides a structured way to detect any synergistic blood-sugar lowering before it becomes clinically significant.

Resveratrol's Estrogenic Activity

Resveratrol is classified as a phytoestrogen. It binds estrogen receptor beta (ERβ) with modest affinity (Ki ~50 nM) and estrogen receptor alpha (ERα) more weakly [11]. At doses of 500 mg daily or higher, circulating metabolites may exert weak estrogenic effects, which is a concern for hormone-sensitive conditions and for men on testosterone replacement therapy.

Clinical Relevance for AOD-9604 Users

AOD-9604 has no known estrogenic or anti-estrogenic activity. The peptide was explicitly designed to retain the lipolytic domain of GH without the growth-promoting or hormonal domains [1]. So the estrogenic concern here is about resveratrol alone, not about an interaction between the two.

Men on TRT who add high-dose resveratrol should monitor estradiol levels at baseline and at 8 weeks. Women with a history of estrogen receptor-positive breast cancer should consult their oncologist before adding resveratrol at any dose, per American Cancer Society guidance [12].

Dose-Separation Strategy

Even though a pharmacokinetic interaction is unlikely, separating administration times is standard practice when combining any peptide with a polyphenol supplement.

Why Separate?

Polyphenols can chelate metal ions and bind to peptide surfaces, potentially reducing peptide absorption if taken simultaneously by mouth [13]. AOD-9604 is most commonly administered subcutaneously, which bypasses this concern entirely. For oral AOD-9604 formulations (marketed as capsules or lozenges under 503A compounding), a 30 to 60 minute gap between resveratrol and AOD-9604 reduces the likelihood of gastrointestinal binding.

Suggested Timing

A practical approach: take AOD-9604 on an empty stomach (morning, fasted), and take resveratrol with a fat-containing meal later in the day. Resveratrol absorption improves modestly with dietary fat [6], and AOD-9604 absorption is best in a fasted state [4].

Monitoring Recommendations

Because both agents have limited long-term safety data in humans, a monitoring framework protects against subclinical adverse effects that would otherwise go unnoticed.

Baseline Labs Before Starting

Draw ALT, AST, fasting glucose, fasting insulin, lipid panel, and (for men on TRT) estradiol and total testosterone before initiating the combination.

Follow-Up at 8 to 12 Weeks

Repeat ALT and AST to screen for hepatotoxicity. A 2011 randomized trial of resveratrol 2,000 mg daily in colorectal cancer patients (N=20) found ALT elevations >2× ULN in 2 of 20 participants [14]. Doses of 250 to 500 mg daily have not produced this signal in larger studies, but adding a second investigational agent justifies the precaution [9].

Ongoing Monitoring

Fasting glucose every 12 weeks if on metformin or insulin. Estradiol every 12 weeks if on TRT. Renal function (BUN, creatinine, eGFR) annually or more frequently if baseline eGFR is <60.

What to Do If You Are Already Taking Both

Many patients start supplements before discussing them with a clinician. If you are already combining resveratrol and AOD-9604 and feel well, that is not a reason to stop abruptly, but it is a reason to get labs drawn.

Step 1: Disclose to Your Provider

Peptides obtained through compounding pharmacies may not appear in a standard medication reconciliation. Mention AOD-9604 by name, including the dose, route, and frequency.

Step 2: Get Baseline Labs

Even retroactively, a hepatic panel and fasting glucose give your clinician something to trend.

Step 3: Note Any New Symptoms

Joint pain, peripheral edema, flushing, or GI upset (nausea, loose stools) should be reported. Resveratrol causes GI symptoms in roughly 15% of users at doses above 500 mg [14]. AOD-9604 can cause injection-site erythema and transient headache [4].

Populations That Should Use Extra Caution

Not every patient faces the same risk profile when stacking these two compounds. Certain groups warrant closer oversight.

Patients on Anticoagulants

Resveratrol inhibits platelet aggregation in vitro and may potentiate warfarin via CYP2C9 inhibition [15]. If you are on warfarin or a direct oral anticoagulant and want to add resveratrol, INR or anti-Xa monitoring should be tightened for the first four to six weeks.

Patients With Hepatic Impairment

Both resveratrol metabolites and peptide fragments require hepatic or renal processing. Patients with Child-Pugh B or C cirrhosis should avoid high-dose resveratrol until safety data exist for that population [14].

Patients on Multiple CYP3A4 Substrates

While resveratrol's CYP3A4 inhibition is clinically weak at standard doses, patients already taking strong CYP3A4 substrates (atorvastatin, certain immunosuppressants, some calcium channel blockers) should discuss the addition of resveratrol at doses above 500 mg with their pharmacist [7].

The Bottom Line on Safety

The theoretical interaction risk between AOD-9604 and resveratrol is low. AOD-9604 is cleared by proteolysis, not by the CYP system that resveratrol modestly inhibits. The pharmacodynamic overlap on AMPK signaling deserves attention only in patients already taking glucose-lowering drugs. Separating doses by 30 to 60 minutes, drawing baseline and follow-up labs, and disclosing both agents to your prescriber is the minimum standard of care for any supplement-peptide stack.

The first human trial examining AOD-9604 co-administration with any supplement has not yet been registered on ClinicalTrials.gov as of May 2026 [16]. Until that changes, the best evidence available is pharmacologic reasoning, not clinical proof.